These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30442095)

  • 21. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis.
    Xin W; Hui Y; Xiaodong Z; Xiangli C; Shihui W; Lihong L
    J Pharm Pharm Sci; 2017; 20(0):168-183. PubMed ID: 28719361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
    Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
    Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation.
    Westall GP; Cristiano Y; Levvey BJ; Whitford H; Paraskeva MA; Paul E; Peleg AY; Snell GI
    Transplantation; 2019 May; 103(5):1005-1013. PubMed ID: 30247316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis.
    Klimczak-Tomaniak D; Roest S; Brugts JJ; Caliskan K; Kardys I; Zijlstra F; Constantinescu AA; Voermans JJC; van Kampen JJA; Manintveld OC
    Transplantation; 2020 Jul; 104(7):1508-1518. PubMed ID: 31644496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L; Bouda M; Jindra P; Reischig T
    Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: Single-center experience.
    Khan S; Fischman C; Huprikar S
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28940831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of cytomegalovirus infection/disease in IgG positive renal transplantation recipients on valaciclovir prophylaxis.
    Sari T; Dursun B; Ceri M; Ergin C; Turgut H; Ozban M
    J Infect Dev Ctries; 2022 Dec; 16(12):1921-1927. PubMed ID: 36753661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
    Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C; Preiksaitis J; Cervera C;
    Transpl Infect Dis; 2018 Oct; 20(5):e12964. PubMed ID: 29981174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.